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may help address some of the infectious complications of
BMT, an approach that is being tested in clinical trials. The
fact thatMP can be cryopreserved and can be used effectively
without being MHC matched to the host enables this
approach.
We have reported in preclinical models that we can use MP
to induce speciﬁc and lasting tolerance for solid organ
transplants. In our model, mice (typically BALB/c) are pre-
conditioned and reconstituted with autologous or allogeneic
hematopoietic stem cells (HSC) and allogeneic MP. MP-
matched skin grafts are placed simultaneously and their fate
is followed long-term. We have established that MP induce
speciﬁc tolerance, MP-matched skin grafts are accepted,
while grafts unmatched to the MP, HSC or host are rejected.
MP from Rag2-/-IL2rg-/- mice that are incapable of produc-
ing B cells, T cells or NK cells, establish that only organ-graft
matched myeloid cells are essential for this process. Toler-
ance can be induced by 100,000 MP in the context of allo-
geneic (third party) HSC transplantation. However, we have
previously reported that the same number of MP only pro-
tects skin grafts in approximately 80% of the recipients that
have been given autologous HSC (Transpl Immunol 31:112-
118,2014).
Here we report that while tolerance induction byMP is more
efﬁcient when combined with allogeneic HSC, increasing the
cell dose ensures the same outcome with autologous HSC.
Injection of 40,000 or more Linneg/lo, Sca-1neg, c-Kit+ MP
induces robust tolerance in recipients of allogeneic HSC.
However, similar results can be obtained in the context of
host-autologous HSC by using slightly higher cell doses
(200,000 or more MP are needed to protect all skin grafts).
We conclude that organ matched MP can induce robust
tolerance for simultaneously or subsequently placed solid
organ transplants, without the need for long-term high level,
multi-lineage engraftment. The speciﬁc properties of MP
(they are clinically available, they can be cryopreserved, they
can be used without matching and MP can be expanded ex
vivo) makes these cells of particular interest. They offer a
new approach to the use of BMT to help in improving solid
organ transplantation.398
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Purpose: Vitamin D deﬁciency has been associated with
chronic Graft Versus Host Disease (GVHD), and insufﬁcient
Vitamin D levels have been shown in patients who have
undergone hematopoietic cell transplant (HCT). This pilot
study tests the hypothesis that Vitamin D deﬁciency is
prevalent and is associated with acute GVHD (AGVHD) in the
immediate 90 days after HCT.
Methods: Fifty allogeneic subjects were selected from the
HCT database based on available bio-samples pretransplant,
30 days, and 90 days post HCT, obtained during 2012-2013.
Retrospective clinical data were also obtained. Liquidchromatography-tandem mass spectrometry (LC-MS/MS)
was used to determine 25-OH vitamin D (D2, D3 and total)
levels at the three time-points. Descriptive analysis was
completed using PASW (IBM, V.20).
Results: 50 subjects (25 male, 25 female), mean age 4111
years, 48% white (18% Asian, 34% other), were selected.
AGVHDwas present in 23/49 (w50%) of subjects and 73% had
Vitamin D deﬁciency at baseline (208 ng/ml), signiﬁcantly
decreasing at 30 days (168 ng/ml, p¼.048), and remained
constant at 90 days (1610 ng/ml). Majority of samples were
below threshold for Vitamin D (<25 ng/ml, 77%), however no
signiﬁcant relationship to AGVHDwas detected (p¼.530). For
sex, men had greater proportion with low Vitamin D (83% v
63%) and AGVHD (52% v 42%) than women, though not
reaching signiﬁcance (p¼.193 & p¼.571). For race, all Asian
subjects were below threshold for Vitamin D (9/9) and 4
developed AGVHD (44%).
Conclusion: We identify a signiﬁcant majority of subjects
undergoing HCT have Vitamin D deﬁciency (73%), progress-
ing 30 days post HCT with a disproportionate effect on sex
and race. Although we do not detect an association between
Vitamin D deﬁciency and AGVHD, an appropriately powered
study is needed to determine whether a relationship exists.
Supplementation andmonitoring HCT patients for Vitamin D
deﬁciency is warranted.399
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Regulatory T cell (Treg) therapy provides an alternative
approach to chronic immunosuppression and has shown
promising results in murine models. Translating this
approach into the clinic depends on developing efﬁcient
methods with which to expand human or non-human pri-
mate Tregs in vitro.
At the Columbia Center for Translational Immunology (CCTI)
we have started a pre-clinical bone marrow transplant pro-
gram using the Cynomolgus macaque (CM) monkey model
involving Tregs to promote tolerance to tissues and organs.
We ﬁrst characterized CM Tregs, which have similar
phenotype when compared to human Tregs. 3.67% of CD4 T
cells in the CM co-express high levels of CD25 and FoxP3
(n¼15) and 3.53% express CD25 and are negative for CD127, a
commonly used Treg marker. Similar to human Tregs, CM
Tregs include naïve or resting Tregs (1.63%) and activated
effector Tregs (2.4%) based on CD45RA expression (n¼7). In
vitro CM CD25hiCD127- (FoxP3+) Tregs were found to be
similarly suppressive as human Tregs, supporting the clinical
relevance of the CM model.
We subsequently aimed to expand polyclonal regulatory T
cells (pTregs) in vitro for use in our transplant studies. We
developed four protocols for the expansion of pTregs over
21-56 days. 50-100 thousand CD4+CD8-CD25hi or CD4+CD8-
CD25hiCD127- Tregs were isolated from 20-30mL of blood
and cultured with IL-2, aCD3, rapamycin and either donor
PBMCs, artiﬁcial APCs (L-cells, murine ﬁbroblast expressing
human CD80, CD58 and CD32) or both. 1000-10,000 fold
